301184-87-2

Upstream product

• 18495-82-4 4-(3-phenylpropyl)piperidine 
• 301184-86-1 (R)-Cyclopentyl-((3R,4S)-3-formyl-4-phenyl-pyrrolidin-1-yl)-acetic acid 4-methoxy-benzyl ester 
• 76000-08-3 4-(3-(phenyl)prop-1-yl)piperidine hydrochloride 
• 301184-84-9 [(3R,4S)-3-(tert-Butyl-dimethyl-silanyloxymethyl)-4-phenyl-pyrrolidin-1-yl]-cyclopentyl-acetic acid 4-methoxy-benzyl ester 
• 301184-85-0 (R)-Cyclopentyl-((3R,4S)-3-hydroxymethyl-4-phenyl-pyrrolidin-1-yl)-acetic acid 4-methoxy-benzyl ester 
• 300853-88-7 (3R,4S)-3-(([tert-butyl(dimethyl)silyl]oxy)methyl)-4-phenylpyrrolidine 

Relevant academic research and scientific papers

1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 4: Synthesis of N-1 acidic functionality affording analogues with enhanced antiviral activity against HIV

A series of α-(pyrrolidin-1-yl)acetic acids is presented as selective and potent antivirals against HIV. Several of the pyrrolidine zwitterions demonstrated reasonable in vitro properties, enhanced antiviral activities and improved pharmacokinetic profiles over pyrrolidine 1.

Pyrrolidine modulators of chemokine receptor activity

The present invention is directed to pyrrolidine compounds of the formula 1: (wherein R1, R2, R3, R4, R5, R6and n are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptors CCR-5 and/or CCR-3.